These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 23862617)

  • 1. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
    Palomino JC; Martin A
    Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.
    Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D
    Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment.
    Lange C; Chesov D; Heyckendorf J; Leung CC; Udwadia Z; Dheda K
    Respirology; 2018 Jul; 23(7):656-673. PubMed ID: 29641838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the research of heterocyclic compounds as antitubercular agents.
    Yan M; Ma S
    ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update.
    De Leon Rodriguez LM; Kaur H; Brimble MA
    Org Biomol Chem; 2016 Jan; 14(4):1177-87. PubMed ID: 26645944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis: current treatment, diagnostics, and newer antitubercular agents in clinical trials.
    Ahsan MJ; Ansari MY; Yasmin S; Jadav SS; Kumar P; Garg SK; Aseri A; Khalilullah H
    Infect Disord Drug Targets; 2015; 15(1):32-41. PubMed ID: 25246035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New tuberculosis drugs on the horizon.
    Cole ST; Riccardi G
    Curr Opin Microbiol; 2011 Oct; 14(5):570-6. PubMed ID: 21821466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.
    Wallis RS; Maeurer M; Mwaba P; Chakaya J; Rustomjee R; Migliori GB; Marais B; Schito M; Churchyard G; Swaminathan S; Hoelscher M; Zumla A
    Lancet Infect Dis; 2016 Apr; 16(4):e34-46. PubMed ID: 27036358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis.
    Ahmad S; Mokaddas E
    J Infect Public Health; 2014; 7(2):75-91. PubMed ID: 24216518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoniazid derivatives and their anti-tubercular activity.
    Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
    Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New perspectives on the treatment of mycobacterial infections using antibiotics.
    He Y; Fan A; Han M; Zhang Y; Tong Y; Zheng G; Zhu S
    Appl Microbiol Biotechnol; 2020 May; 104(10):4197-4209. PubMed ID: 32185432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa.
    Streicher EM; Müller B; Chihota V; Mlambo C; Tait M; Pillay M; Trollip A; Hoek KG; Sirgel FA; Gey van Pittius NC; van Helden PD; Victor TC; Warren RM
    Infect Genet Evol; 2012 Jun; 12(4):686-94. PubMed ID: 21839855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential role of trimethoprim-sulfamethoxazole in the treatment of drug-resistant tuberculosis.
    Palomino JC; Martin A
    Future Microbiol; 2016; 11(4):539-47. PubMed ID: 27070731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of recent advances in anti-tubercular drug development.
    Umumararungu T; Mukazayire MJ; Mpenda M; Mukanyangezi MF; Nkuranga JB; Mukiza J; Olawode EO
    Indian J Tuberc; 2020 Oct; 67(4):539-559. PubMed ID: 33077057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.